SCHEMBL21589019

SCHEMBL21589019

Cc1c[nH]c2nc(Cl)ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.40
ADORA1 P30542 6/20 0.38
ATM Q13315 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
KDM4E B2RXH2 2/20 0.35
GMNN O75496 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
PKM P14618 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
MTOR P42345 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
HIF1A Q16665 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7922469 0.79 ADORA2A (0.53) ADORA2AADORA1KDM4EMEN1KMT2A
SCHEMBL21589017 0.76 ADORA2A (0.40) ADORA2AADORA1SIRT2KDM4EGMNN
SCHEMBL20455615 0.76 ADORA2A (0.40) ADORA2AADORA1SIRT2KDM4EGMNN
SCHEMBL21273862 0.76 AXL (0.48) ADORA2AADORA1SIRT2KDM4EGMNN
SCHEMBL15333269 0.76 CDK5 (0.46) ADORA2AADORA1ATMKDM4EPDE4A
SCHEMBL20354739 0.76 ADORA2A (0.40) ADORA2AADORA1SIRT2KDM4EGMNN
SCHEMBL7024233 0.73 ADORA2A (0.50) ADORA2AADORA1KDM4EHSD17B10PIM1
SCHEMBL24324039 0.72 CCR1 (0.39) ADORA2AADORA1ATMKDM4EPDE4A
SCHEMBL21274452 0.72 LRRK2 (0.53) ADORA2ADYRK1A
SCHEMBL23106895 0.72 TGFBR1 (0.36) ADORA2AADORA1ATMKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 EP disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US disclosed
EP-4269402-A1 AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF GT Apeiron Therapeutics Limited (HK) 2023-11-01 EP disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 US disclosed
WO-2022134641-A1 AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 湃隆生物科技有限公司(香港) 2022-06-30 WO disclosed
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 US disclosed
WO-2019233438-A1 KINASE SELECTIVE INHIBITOR 北京大学深圳研究生院 (CN) 2019-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP ADORA2A 1246/4885ADORA1 1697/4885ATM 3465/4885
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP ADORA2A 1252/4885ADORA1 1706/4885ATM 3517/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP ADORA2A 1252/4885ADORA1 1706/4885ATM 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.